Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 705 clinical trials
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

primary cancer
cancer
metastatic cancer
FGFR2
  • 154 views
  • 14 Dec, 2020
  • 155 locations
featured
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

lung cancer
epidermal growth factor
EGFR
erlotinib
growth factor
  • 100 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease.

We are currently recruiting participants for a clinical research study to evaluate the efficacy of an investigational medication in adults with Diabetic Kidney Disease.

diabetes
diabetic complication
hemoglobin a1c
diabetic chronic kidney disease
kidney function tests
  • 12 views
  • 17 May, 2021
  • 1 location
featured
  • 74 views
  • 08 Nov, 2020
  • 1 location
featured
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

growth factor. The growth factor (granulocyte colony stimulating factor) is designed to increase the production of donor stem cells. In the second step white blood cell lymphocytes are removed from

  • 194 views
  • 22 Dec, 2020
  • 1 location
featured
A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Background: People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells. The treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the disease may return in 1 …

anemia studies
myelodysplastic syndrome (mds)
anemia
aplastic anemia
myelodysplastic syndromes
  • 61 views
  • 22 Dec, 2020
  • 1 location
featured
Diabetic Neuropathy in Type 1 and 2 Diabetics

Diabetic Neuropathy in Type 1 and 2 Diabetics

  • 2896 views
  • 25 Mar, 2021
  • 1 location
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 cetuximab. Study treatment continues until disease progression or unacceptable toxicity (ie, not for a fixed number of courses). The primary endpoint of the …

growth factor
modified folfox6
measurable disease
adenocarcinoma
neutrophil count
  • 7 views
  • 22 Jan, 2021
  • 1 location
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor

growth factor
pembrolizumab
transitional cell carcinoma
renal function
advanced urothelial carcinoma
  • 271 views
  • 03 Jun, 2021
  • 588 locations
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared With Carboplatin-Pemetrexed in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

  • 0 views
  • 24 Jun, 2021
  • 273 locations